Clinical trials: Mood Disorders
Premenstrual Dysphoric Disorder
Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD
Purpose: Using transcranial alternating current stimulation (tACS), we will study whether tACS induces changes in prefrontal alpha oscillatory frequencies in women with premenstrual dysphoric disorder (PMDD) and whether tACS…
- Trial name
- NCT02362191
- Testing
- Alternating Current Stimulator
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Anhedonia
Study to Treat Major Depressive Disorder With a New Medication
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener ezogabine (Potiga…
- Trial name
- NCT03043560
- Testing
- Ezogabine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- James Murrough
Depression, Postpartum
Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset
The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS therapy in women who have postpartum depression.
- Trial name
- NCT01842542
- Testing
- NeuroStar Transcranial Magnetic Stimulation (TMS)
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Neuronetics
Post Partum Depression
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
- Trial name
- NCT03665038
- Testing
- Brexanolone
- Where
- 17 sites in United States
- Volunteers
- 28 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Disorder
Short Term Rescue Study of Olanzapine
We will assess the effect of olanzapine compared to placebo added to prior treatment on CGI-S in a one-week randomized double-blind study.
- Trial name
- NCT00186017
- Testing
- Olanzapine/Zyprexa
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission
KAP for Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused…
- Conditions
- Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
- Trial name
- KReDO (NCT05193318)
- Testing
- Ketamine-assisted psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term…
- Trial name
- NCT03538691
- Testing
- Brexpiprazole, Antidepressant therapy
- Where
- United States
- Volunteers
- 1,149 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD.
- Trial name
- B2411003 (NCT00770289)
- Testing
- Cohort
- Where
- 3 sites in Greece
- Volunteers
- 851 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder, Bipolar Disorder
Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
This study proposes to examine the potential safety and efficacy of ziprasidone for patients with anxiety and bipolar disorder on anxiety outcomes, bipolar symptoms, and on measures of quality of life and resilience.
- Trial name
- NCT00374543
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Perinatal Depression, Post Partum Depression
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
The proposed study involves experimentally manipulating reproductive hormones in nonpregnant, euthymic women to create a scaled down version of the changes that occur during pregnancy and the postpartum period.
- Conditions
- Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
- Trial name
- NCT04051320
- Testing
- Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major, Postpartum Depression
Mommy-Baby Treatment for Perinatal Depression
Perinatal depression is a major public health problem, affecting 15% of women during pregnancy through the postpartum period, with adverse consequences for the mother, the fetus, the infant, and the family.
- Trial name
- NCT01744041
- Testing
- Dyadic Interpersonal Psychotherapy, Enhanced Treatment as Usual
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Insomnia, Major Depressive Disorder
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.
- Trial name
- NCT02669082
- Testing
- Ramelteon
- Where
- 7 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Takeda
Bipolar Disorder Depression
Minocycline and Aspirin in the Treatment of Bipolar Depression
The purpose of this study is to determine whether minocycline and aspirin are effective in the treatment of depression in individuals with bipolar disorder.
- Trial name
- Minocycline (NCT01429272)
- Testing
- Minocycline, Aspirin
- Where
- 3 sites in United States
- Volunteers
- 99 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Bipolar Disorder
Genetic Predictors of Lithium Response in Bipolar Disorder
The purpose of this study is to identify genetic predictors of lithium response in bipolar disorder.
- Trial name
- NCT00252577
- Testing
- Lithium treatment
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Depression
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode
- Trial name
- NCT03288714
- Testing
- Synchronized Transcranial Magnetic Stimulation (sTMS)
- Where
- 14 sites in United States
- Volunteers
- 121 people
- Sponsor
- Wave Neuroscience
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Disorder, Anxiety Disorders
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
Pediatric Bipolar Disorder (BD) is uncommon in children. Its symptoms include periods of manic behavior (being overly happy or giddy, feeling grandiose, feeling a decreased need for sleep, having too much energy, moving more than…
- Conditions
- Bipolar Disorder, Anxiety Disorders, Bipolar Affective Disorder, Bipolar Depression
- Trial name
- NCT00805493
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)
The primary objective of this trial was to characterize the long-term (up to 40 weeks) safety and tolerability of asenapine in bipolar I disorder subjects who had not completely responded to continuing treatment with lithium or…
- Trial name
- NCT00145509
- Testing
- Asenapine
- Volunteers
- 77 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.